Termuhlen P M, Curley S A, Talamonti M S, Saboorian M H, Gallick G E
Department of Surgery, University of Texas M.D. Anderson Cancer Center, Houston 77030.
J Surg Res. 1993 Apr;54(4):293-8. doi: 10.1006/jsre.1993.1046.
The c-src proto-oncogene has been implicated in the progression of primary human colorectal carcinoma to hepatic metastasis. To determine if increased pp60c-src tyrosine kinase activity is a colon-specific phenomenon present in colorectal metastases to all sites, the pp60c-src-specific kinase activity of noncolon tumor metastases to the liver was compared to that of colorectal liver metastases. Activity of extrahepatic colon carcinoma metastases was compared to that of colorectal liver metastases as well as that of normal colonic mucosa. The specific activity of pp60c-src in multiple synchronous metastases from colon carcinoma was also examined. Tyrosine kinase activity was determined by immune complex kinase assay; protein levels were determined by immunoblotting. Specific activity was calculated for each group by dividing the total activity by protein level. Colon carcinoma metastases to the liver had significantly (P < 0.04) increased pp60c-src activity with an average 2.2-fold increase over normal mucosa. In contrast, noncolon tumor metastases to the liver showed minimal pp60c-src kinase activity. Extrahepatic colorectal metastases demonstrated significantly increased (P < 0.005) pp60c-src activity with an average 12.7-fold increase over normal mucosa. When compared to colon liver metastases, extrahepatic colorectal tumor metastases show a significant difference in activity (P < 0.05) with an average 5.7-fold increase. Examination of multiple synchronous colon carcinoma metastases confirmed these results. In summary, we conclude that (1) the activation of pp60c-src between primary tumors and metastases is specific to colon metastases, and (2) although pp60c-src activity is significantly increased in colorectal metastases, site-specific differences in the magnitude of activity are evident.
原癌基因c-src与原发性人类结直肠癌向肝转移的进展有关。为了确定pp60c-src酪氨酸激酶活性增加是否是所有部位结直肠癌转移中存在的结肠特异性现象,将非结肠肿瘤肝转移灶的pp60c-src特异性激酶活性与结直肠癌肝转移灶的进行了比较。还比较了肝外结肠癌转移灶与结直肠癌肝转移灶以及正常结肠黏膜的活性。此外,还检测了结肠癌多个同步转移灶中pp60c-src的比活性。酪氨酸激酶活性通过免疫复合物激酶测定法测定;蛋白质水平通过免疫印迹法测定。通过将总活性除以蛋白质水平来计算每组的比活性。结肠癌肝转移灶的pp60c-src活性显著增加(P < 0.04),平均比正常黏膜增加2.2倍。相比之下,非结肠肿瘤肝转移灶的pp60c-src激酶活性极低。肝外结直肠癌转移灶的pp60c-src活性显著增加(P < 0.005),平均比正常黏膜增加12.7倍。与结肠癌肝转移灶相比,肝外结直肠癌转移灶的活性有显著差异(P < 0.05),平均增加5.7倍。对多个同步结肠癌转移灶的检测证实了这些结果。总之,我们得出结论:(1)原发性肿瘤与转移灶之间pp60c-src的激活是结肠转移所特有的;(2)尽管pp60c-src活性在结直肠癌转移中显著增加,但活性程度存在部位特异性差异。